- Pickering GW. High blood pressure. Graeme & Stratton, New York, 1968: chapters 10 and 11, pp. 203-35.
- Platt R. The nature of essential hypertension. Lancet 1959; 2: 1092-5.
- McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
- Evans VG, Rose GA. Hypertension. Br Med Bull 1971; 27: 32-42.
- Chalmers J. The treatment of hypertension. Br J Clin Pharm 1996; 42: 29-35.
- Joint National Committee on Detectioa Evaluation, and Treatment of High Blood Pressure. The sixth report of the National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46.
- Guidelines Subcommittee. 1999. World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Eng J Med 2000; 342: 145.53.
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotectiveeffect of the angiotensin-receptor antagonist irbesartan inpatients with nephropathy due to type 2 diabetes. N Engl JMed 2001; 345: 851-60.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
- Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
- Vason RS, Larson MG, Leip EP, et al. Impact of highnormal blood pressure on the risk of cardiovascular disease. N Engl. J Med 2001; 345: 1291-7.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351; 1755-62.
- Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-746.
- World Health Organisation-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomised trials of blood pressure lowering treatments. J Hypertens 1998; 16; 127-37.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE Inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
Blood Pressure
Volume 11, 2002 - Issue 2